Advanced Non-Squamous and Squamous NSCLC Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Advanced Non-Squamous and Squamous NSCLC Market is segmented By Molecule Type (Monoclonal antibody, Small molecule, Peptide), By Treatment (Immunotherapy, Chemotherapy), By Disease (Non-Squamous Cell Carcinoma, Squamous Cell Carcinoma), By Route of Administration (Oral, Subcutaneous, Intravitreal, Intramuscular), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Advanced Non-Squamous and Squamous NSCLC Market Size
Market Size in USD
CAGR7%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 7% |
| Market Concentration | High |
| Major Players | AstraZeneca, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine |
please let us know !
Advanced Non-Squamous and Squamous NSCLC Market Analysis
The advanced non-squamous and squamous NSCLC market is estimated to be valued at USD 10.89 Bn in 2024 and is expected to reach USD 16.58 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031. This market has been witnessing steady growth over the past few years and this trend is expected to continue over the forecast period supported by increasing prevalence of lung cancer cases globally and growing demand for advanced and effective therapeutic options for treatment.